COVID-19 Funding Opportunities

I.) Internal Opportunities
Rebuild, Renew, Reshape to Study COVID-19 Recovery
How can communities and society recover from the COVID-19 global pandemic and evolve to a new normal that is not only more resilient to future shocks but also sustainable and just? The new Rebuild, Renew, Reshape initiative at Ohio State will support interdisciplinary research on the sustainability, resilience and justice dimensions of the COVID-19 recovery. The initiative kicks off with a series of virtual mini workshops 9:30-11 a.m. on Oct. 23, Oct. 30 and Nov. 6, to brainstorm ideas. Interdisciplinary teams that emerge from these workshops will receive help in developing, growing and sustaining their efforts.
Deadline: October 14, 2020

II.) National Science Foundation (NSF)
Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19
NSF is seeking Phase I SBIR/STTR proposals focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis.
Deadline: December 3, 2020

III.) National Institutes of Health (NIH)
Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01 - Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) encourages applications to implement and evaluate community interventions testing 1) the impacts of mitigation strategies to prevent COVID-19 transmission in NIH-designated health disparity populations and other vulnerable groups; and 2) already implemented, new, or adapted interventions to address the adverse psychosocial, behavioral, and socioeconomic consequences of the pandemic on the health of these groups.
Deadline: December 1, 2020

Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 - Clinical Trial Optional)
This FOA aims to support research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and future public health emergencies, including pandemics. The purpose of this funding opportunity is to focus on the role and impact of digital health interventions to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations.
Deadline: December 2, 2020; March 2, 2021

National Institute of General Medical Sciences (NIGMS)
Predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants). Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection; rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR grants only).
Deadline: Rolling through February 6, 2021
COVID-19 Funding Opportunities

**National Institute of Allergy and Infectious Diseases (NIAID)**
NOSI: Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). Topics include: Viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.
**Deadline:** Rolling, through March 25, 2021

**National Institute of Drug Abuse (NIDA)**
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus. NIDA is interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.
**Deadline:** Rolling, through March 31, 2021

**National Institute of Allergy and Infectious Diseases (NIAID) - Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)**
The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).
**Deadline:** Rolling, through April 30, 2021

**IV. Other US Funding Agencies**

**Biomedical Advanced Research and Development Authority (BARDA)**
BARDA has updated its Broad Agency Announcements (BAAs) to focus exclusively on addressing the COVID-19 threat. BARDA, with a total budget of $512 Million, is seeking proposals for projects related to products to diagnose, prevent or treat novel coronavirus infections.
**Deadline:** Rolling, through 10/31/2020

**Fast Grants**
Fast grants are available exclusively to PIs at academic institutions already working on COVID-19 related projects that could help with the pandemic within the next six months.
**Due Date:** Rolling, award decisions made in 48 hours

**Wellcome, Bill & Melinda Gates Foundation, and Mastercard**
The Bill & Melinda Gates Foundation, Wellcome, and Mastercard have committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The Accelerator is seeking partners for the following activities:
- Identifying candidate compounds by testing approved drugs for activity against COVID-19, screening libraries of compounds with confirmed safety data, and considering new investigational compounds and monoclonal antibodies.
- Developing drugs or monoclonal antibodies that pass initial screening.
- Scaling up production and commercialization of successful drugs and monoclonal antibodies.
**Deadline:** Not Specified